Zynex, Inc. (ZYXIQ) Stock Analysis

Zynex, Inc. (ZYXIQ) Healthcare & Pipeline Overview

Zynex, Inc. specializes in medical devices for pain management and rehabilitation, offering products like the NexWave and NeuroMove. Trading on the OTC market after filing for Chapter 11 bankruptcy in December 2025, the company faces challenges in a competitive medical device distribution landscape.

What Is the Investment Thesis for ZYXIQ?

Zynex, Inc. faces significant challenges following its Chapter 11 bankruptcy filing in December 2025. The company's future hinges on its ability to successfully reorganize and regain market confidence. Key factors to consider include the restructuring plan, potential for debt reduction, and the ability to maintain and grow its market share in the pain management and rehabilitation device sector. The company's gross margin of 71.6% indicates potential profitability if operational efficiencies can be improved. However, the negative profit margin of -68.4% and current trading on the OTC market reflect substantial financial distress. Investors should closely monitor the bankruptcy proceedings and any news regarding the company's reorganization efforts.

Based on FMP financials and quantitative analysis

ZYXIQ Key Highlights

Gross Margin of 71.6% indicates potential for profitability if operational efficiencies are improved.

• Negative Profit Margin of -68.4% reflects significant financial challenges.
• Chapter 11 bankruptcy filing on December 15, 2025, introduces substantial uncertainty.
• Trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
• Beta of 1.08 suggests the stock price is slightly more volatile than the market average.

Who Are ZYXIQ's Competitors?

ZYXIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZYXIQ's Key Strengths?

Proprietary technology in electrical stimulation.

• Direct sales force with established relationships.
• High gross margin (71.6%).
• Diverse product portfolio in pain management and rehabilitation.

What Are ZYXIQ's Weaknesses?

Chapter 11 bankruptcy filing.

• Negative profit margin (-68.4%).
• Trading on the OTC market.
• Dependence on direct sales force.

What Could Drive ZYXIQ Stock Higher?

Bankruptcy reorganization plan approval and implementation.

• Potential for debt restructuring and improved financial stability.
• Launch of new fluid monitoring systems (CM-1500, CM-1600).
• Strategic partnerships with healthcare providers.
• Expansion into international markets.

What Are the Key Risks for ZYXIQ?

Financial-distress signal — its Altman Z-Score of -5.00 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Uncertainty surrounding the bankruptcy proceedings.
• Failure to successfully reorganize and emerge from bankruptcy.
• Increased competition in the medical device industry.
• Regulatory changes and compliance requirements.
• Limited financial disclosure and liquidity on the OTC market.

What Are the Growth Opportunities for ZYXIQ?

• Expansion of Fluid Monitoring Systems: Zynex's development of the Zynex Fluid Monitoring System (CM-1500) and Zynex Wireless Fluid Monitoring System (CM-1600) presents a growth opportunity in the non-invasive patient monitoring market. Successful commercialization of these products could diversify Zynex's revenue streams and enhance its market position.
• Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with hospitals, clinics, and rehabilitation centers could expand Zynex's market reach and accelerate product adoption. Collaborating with established healthcare providers can provide access to a wider customer base and enhance the company's credibility. These partnerships can be structured as distribution agreements or joint ventures, allowing Zynex to leverage the existing infrastructure and expertise of its partners.
• Product Innovation and Technological Advancements: Investing in research and development to enhance its existing product line and develop new medical devices can drive long-term growth. Focusing on technological advancements, such as wireless connectivity and remote monitoring capabilities, can differentiate Zynex's products from competitors and attract a wider customer base. This includes further development of the NiCO CO-Oximeter and HemeOx tHb Oximeter.
• Expansion into International Markets: Expanding its sales and marketing efforts into international markets can unlock new growth opportunities for Zynex. Targeting regions with a growing demand for pain management and rehabilitation solutions can diversify its revenue streams and reduce its reliance on the U.S. market. This expansion could involve establishing partnerships with local distributors or setting up its own sales offices in key international markets.
• Focus on Telehealth and Remote Patient Monitoring: With the increasing adoption of telehealth and remote patient monitoring, Zynex can capitalize on this trend by integrating its devices with telehealth platforms and developing remote patient monitoring solutions. This can improve patient access to care, reduce healthcare costs, and enhance patient outcomes. Integrating its devices with telehealth platforms can provide a competitive advantage and drive long-term growth.

What Threats Does ZYXIQ Face?

• Intense competition in the medical device industry.
• Regulatory changes and compliance requirements.
• Economic downturn affecting healthcare spending.
• Potential product liability claims.

What Are ZYXIQ's Competitive Advantages?

• Proprietary technology in electrical stimulation devices.
• Direct sales force providing customer support and training.
• Established relationships with physicians and therapists.
• Brand recognition in the pain management and rehabilitation market.

What Does ZYXIQ Do?

Founded in 1996 and headquartered in Englewood, Colorado, Zynex, Inc. designs, manufactures, and markets medical devices aimed at treating chronic and acute pain, as well as facilitating muscle activation and exercise for rehabilitation purposes. The company's flagship product, NexWave, is a dual-channel, multi-modality device utilizing interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES). Other products include NeuroMove, an electromyography and electric stimulation technology device, and InWave, an electrical stimulation product designed for the treatment of female urinary incontinence, along with E-Wave and M-Wave NMES devices. Zynex also supplies private-labeled products, such as electrodes and batteries, essential for the operation of its electrotherapy devices. Furthermore, Zynex distributes products like Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, rehabilitation braces for knee and wrist support, and Dynacomp for cold compression therapy. The company is also involved in the development of fluid monitoring systems, including the Zynex Fluid Monitoring System (CM-1500) and the Zynex Wireless Fluid Monitoring System (CM-1600), as well as patient monitoring devices like the NiCO CO-Oximeter and HemeOx tHb Oximeter. Zynex sells its products primarily through a direct sales force in the United States. On December 15, 2025, Zynex, Inc. filed for Chapter 11 bankruptcy.

What Products and Services Does ZYXIQ Offer?

• Designs and manufactures medical devices for pain management.
• Offers electrical stimulation devices for chronic and acute pain relief.
• Provides devices for muscle activation and rehabilitation.
• Develops fluid monitoring systems for patient care.
• Distributes private-labeled electrodes and batteries for electrotherapy.
• Sells products through a direct sales force in the United States.

How Does ZYXIQ Make Money?

• Designs, manufactures, and markets medical devices.
• Generates revenue through direct sales of its products.
• Supplies private-labeled products to other companies.
• Focuses on pain management and rehabilitation markets.

What Industry Does ZYXIQ Operate In?

Zynex, Inc. operates within the medical device distribution industry, a sector characterized by technological advancements, regulatory scrutiny, and evolving patient needs. The industry is competitive, with companies vying for market share through product innovation, strategic partnerships, and effective distribution networks. Market trends include a growing demand for non-invasive pain management solutions and increasing adoption of telehealth and remote patient monitoring technologies. Zynex's focus on electrical stimulation devices positions it within a niche market, but the company faces competition from larger, more established players like ECOR, EVAX, GBIO, HYPD, and JSPR.

Who Are ZYXIQ's Key Customers?

• Physicians specializing in pain management.
• Therapists and rehabilitation centers.
• Hospitals and clinics.
• Patients seeking pain relief and rehabilitation.

Wall Street analysts project Zynex, Inc. revenue of about $101.2M for fiscal 2026, with EPS near $-0.48.

Zynex, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.00 places it in the distress zone, a signal of elevated financial risk.

Zynex, Inc. (ZYXIQ) Valuation Context

Valued at $1.69M, ZYXIQ is classified as a micro-cap stock.

The most recent 7 insider filings for Zynex, Inc. break down as 2 sales and 5 purchases. On net that is roughly 35K shares acquired (about $18K) — insiders putting money in tends to read as conviction.

ZYXIQ Financials

ZYXIQ Latest News

No recent news available for ZYXIQ.

Zynex, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources